Skip to content

Study · In vitro (cell-free) · 2015

4 results

Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3 (IGFBP3) and Regulates Its Interaction with Importin-β.

Njomen E, Evans HG, Gedara SH, Heyl DL

Protein and peptide letters1 Jan 2015Cited by 27 (Europe PMC)

PMID26216267 (opens in a new tab)DOI10.2174/0929866522666150728114955 (opens in a new tab)PepBankPUB-26216267
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    In vitro, full-length humanin bound to IGFBP3 with a Kd of 5.05 µM.

    In plain wordsIn lab tests, humanin bound to the protein IGFBP3.

    Peptide
    Humanin
    Outcome
    Not applicableHumanin binding to IGFBP3
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Kd
    5.05 µM
    humanin to IGFBP3

    Source sentences

    Summary
    humanin binds to IGFBP3 with a Kd of 5.05 µM
    1 context sentence
    Summary · context
    We have examined the effect of full-length humanin and a synthetic analogue (HN 3-19), known to be sufficient for its neuroprotective function, on the interaction between IGFBP3 and importin-β1.
  2. 02LabIn vitro (cell-free)Activity measurement

    In vitro, full-length humanin interfered with the binding of importin-β1 to IGFBP3 with an IC50 of 18.1 µM.

    In plain wordsIn lab tests, humanin interfered with the binding of two proteins, importin-β1 and IGFBP3.

    Peptide
    Humanin
    Outcome
    Not applicableInterference of humanin with importin-β1 binding to IGFBP3
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    IC50
    18.1 µM
    importin-β1 binding to IGFBP3

    Source sentences

    Summary
    both humanin (IC50 of 18.1 µM) and HN 3-19 (IC50 of 10.3 μM) interfere with the binding of importin-β1 to IGFBP3 in vitro.
    1 context sentence
    Summary · context
    We have examined the effect of full-length humanin and a synthetic analogue (HN 3-19), known to be sufficient for its neuroprotective function, on the interaction between IGFBP3 and importin-β1.

Studies that did not test the peptide alone2

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

  1. 03LabNot a test of Humanin aloneIn vitro (cells)Efficacy outcome

    In a human lung adenocarcinoma cell line, the humanin fragment HN 3-19 reduced the rate of apoptosis.

    In plain wordsIn cells, the humanin fragment HN 3-19 reduced cell death in a human lung cancer cell line.

    Peptide
    Humanin
    Outcome
    DecreaseApoptosis rate in a lung adenocarcinoma cell line
    Study

    humann: not reported in source

    human lung adenocarcinoma cell line
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    We also demonstrated that HN 3-19 is able to reduce the rate of apoptosis in a human lung adenocarcinoma cell line, suggesting a possible mechanism of action for humanin as an inhibitor of IGFBP3 nuclear translocation.
    1 context sentence
    Summary · context
    We have examined the effect of full-length humanin and a synthetic analogue (HN 3-19), known to be sufficient for its neuroprotective function, on the interaction between IGFBP3 and importin-β1.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  2. 04LabNot a test of Humanin aloneIn vitro (cell-free)Activity measurement

    In vitro, the humanin fragment HN 3-19 interfered with the binding of importin-β1 to IGFBP3 with an IC50 of 10.3 µM.

    In plain wordsIn lab tests, the humanin fragment HN 3-19 interfered with the binding of importin-β1 to IGFBP3.

    Peptide
    Humanin
    Outcome
    Not applicableInterference of HN 3-19 with importin-β1 binding to IGFBP3
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    IC50
    10.3 µM
    importin-β1 binding to IGFBP3

    Source sentences

    Summary
    both humanin (IC50 of 18.1 µM) and HN 3-19 (IC50 of 10.3 μM) interfere with the binding of importin-β1 to IGFBP3 in vitro.
    1 context sentence
    Summary · context
    We have examined the effect of full-length humanin and a synthetic analogue (HN 3-19), known to be sufficient for its neuroprotective function, on the interaction between IGFBP3 and importin-β1.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.